Oct 01, 2015

Gene therapy doubles survival in recurrent glioblastoma | EurekAlert! Science News

An experimental gene therapy essentially doubled the overall survival of patients with recurrent glioblastoma compared to the current standard of care, a researcher said Oct. 1 at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio.

Proceed to the page: http://linkis.com/2XQU9

Similar Articles Added Earlier

  • Generic Heart Medication Shown to Prolong Ovarian Cancer Patients’ Survival

    In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers...

  • PTSD patients sue Colorado over marijuana decision

    DENVER (AP) — Colorado's decision not to allow marijuana to treat post-traumatic stress disorder has prompted a lawsuit by PTSD sufferers. Five PTSD patients filed suit Thursday in Denver District Court. They're challenging a July decision by the Colorado Board of Health not to make PTSD the first...

  • Study: Best Heath & fitness apps according ...

    People runningWith tens of thousands of health-related apps to choose from, it can be difficult for clinicians to know which ones to recommend to their patients to help them monitor and improve their diet, weight, sleep, and exercise habits. A new analysis from a University of Texas Health Science...

  • Cancer Breakthrough: Probiotics may Save Patients from Deadly Chemotherapy | World Truth.TV

    If you or someone you love is facing the possibility of cancer or chemotherapy, make sure they read this story. Breakthrough new science conducted at the University of Michigan and about to be published in the journal Nature reveals that intestinal health is the key to surviving chemotherapy. The...

  • Roche - Two positive studies of Roche’s i...

    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from two phase II studies that evaluated the investigational cancer immunotherapy atezolizumab (anti-PDL1; MPDL3280A) in people with advanced non-small cell lung cancer (NSCLC). In the randomised phase II study, POPLAR...

Similar Articles Added Today

Latest Links Processed

0/120